Mirvetuximab
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα) -targeting ADC (Mirvetuximab soravtansine) . Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research[1][2][3].
Product Specifications
CAS Number
1453084-36-0
Product Name Alternative
M9346A
UNSPSC
12352203
Target
ADC Antibody; Antifolate
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mirvetuximab.html
Purity
99.88
Solubility
10 mM in DMSO
Smiles
[Mirvetuximab]
Molecular Weight
(145.2 kDa)
References & Citations
[1]Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35 (10) :1112-1118.|[2]Loebrich S, et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 2017 Jul;19 (4) :1223-1234.|[3]Ab O, et al. IMGN853, a Folate Receptor-α (FRα) -Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14 (7) :1605-13.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog